Performance evaluation of the Specific Reveal system for rapid antibiotic susceptibility testing from positive blood cultures containing Gram-negative pathogens
Journal of Clinical Microbiology · 11.12.2024 · 62 (12)
DOI: 10.1128/jcm.00692-24 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 11.12.2024. Verfasst von Greta Ostermann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Wisplinghoff Laboratories, Cologne, Germany. Hauptthemen laut MEDLINE: Microbial Sensitivity Tests, Gram-Negative Bacteria, Anti-Bacterial Agents, Blood Culture. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Rapid antimicrobial drug administration is crucial for the efficient treatment of sepsis or septic shock, but empirical therapy is limited by the increasing prevalence of multidrug-resistant bacteria. Thus, rapid and reliable antimicrobial susceptibility testing (AST) is needed to start appropriate antimicrobial drug administration as quickly as possible. In the present study, we evaluated the performance of the Reveal rapid AST system. From February to April 2021, 102 positive blood culture bottles (BCBs) from hospitalized patients with bacteremia caused by Gram-negative bacteria were included in the study. All isolates were tested by the Reveal system directly from the positive BCBs in comparison to the DxM MicroScan WalkAway. Essential agreement (EA) and category agreement (CA) were high with 98.5% and 97.1%, respectively. We also determined the susceptibility of 10 highly resistant CDC & FDA AR strains in duplicate. Here, EA was 99.6% and CA 97.9%. The average time to result by Reveal was 5.4 h ± 1.2 h compared to an average of 16 h by DxM MicroScan WalkAway for clinical strains and 3.8 h ± 1.2 h for more resistant CDC & FDA AR strains. Susceptibility determination with the Reveal rapid AST system directly from positive BCBs is for the frequently represented bug-drug combinations a reliable and accurate approach, meeting the European ISO guideline for the performance of AST systems. Moreover, AST directly from blood cultures performed with the Reveal system saves time when compared to the conventional AST, as no subculturing is needed and time to result is very short.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wisplinghoff Laboratories, Cologne, Germany.
- Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany.
- Specific Diagnostics, San Jose, California, USA.
- Cellular Longevity, Inc, San Francisco, California, USA.
- Institute for Virology and Medical Microbiology, Witten/Herdecke University, Witten, Germany.
ORCID-Profile: Greta Ostermann, Barbara Körber-Irrgang, Nathalie Jazmati
Zitieren
APA
Ostermann, G., Körber-Irrgang, B., Krüger, A., Singh, P., Vo, K., Gielen, J., Aurbach, U., Wisplinghoff, H., & Jazmati, N. (2024). Performance evaluation of the Specific Reveal system for rapid antibiotic susceptibility testing from positive blood cultures containing Gram-negative pathogens. Journal of Clinical Microbiology, 62(12). https://doi.org/10.1128/jcm.00692-24
Vancouver
Ostermann G, Körber-Irrgang B, Krüger A, Singh P, Vo K, Gielen J, et al. Performance evaluation of the Specific Reveal system for rapid antibiotic susceptibility testing from positive blood cultures containing Gram-negative pathogens. Journal of Clinical Microbiology. 2024;62(12). doi:10.1128/jcm.00692-24
BibTeX
@article{Ostermann2024,
author = {Ostermann, Greta and Körber-Irrgang, Barbara and Krüger, Alexander and Singh, Pragya and Vo, Kenny and Gielen, Jörg and Aurbach, Ute and Wisplinghoff, Hilmar and Jazmati, Nathalie},
title = {Performance evaluation of the Specific Reveal system for rapid antibiotic susceptibility testing from positive blood cultures containing Gram-negative pathogens},
journal = {Journal of Clinical Microbiology},
year = {2024},
volume = {62},
number = {12},
doi = {10.1128/jcm.00692-24}
}
EUVIMED